Tuis4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Vorige sluiting
¥2 244,00
Dagwisseling
¥2 247,00 - ¥2 274,00
Jaarwisseling
¥1 921,00 - ¥2 411,00
Markkapitalisasie
119,94 mjd JPY
Gemiddelde volume
63,62 k
P/V-verhouding
11,86
Dividend-opbrengs
1,99%
Primêre beurs
TYO
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 20,97 mjd | 14,11% |
Bedryfskoste | 12,52 mjd | 14,20% |
Netto inkomste | 1,85 mjd | -25,47% |
Netto winsgrens | 8,82 | -34,67% |
Wins per aandeel | — | — |
EBITDA | 4,39 mjd | 8,29% |
Effektiewe belastingkoers | 17,59% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 24,36 mjd | 31,90% |
Totale bates | 158,34 mjd | 6,87% |
Totale aanspreeklikheid | 69,77 mjd | -3,36% |
Totale ekwiteit | 88,57 mjd | — |
Uitstaande aandele | 44,08 m | — |
Prys om te bespreek | 1,12 | — |
Opbrengs op bates | 4,06% | — |
Opbrengs op kapitaal | 4,89% | — |
Kontantvloei
Netto kontantverandering
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 1,85 mjd | -25,47% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
HUB
Gestig
22 Des. 1955
Webwerf
Werknemers
1 777